ENGNW
enGene Holdings Inc. Warrants
NASDAQ · Healthcare · Biotechnology · CA
$0.21
−4.55%Price chart
Jul 22Jul 30Aug 6Aug 14Aug 21Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.7x
Market Cap
$10.74M
MomentumView details →
1D Return
−4.55%
YTD Return
−92.91%
RSI (14)
46.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.7x
Market Cap
$10.74M
RSI (14)
46.3
MomentumView details →
1D Return
−4.55%
YTD Return
−92.91%
SummaryUpdated Apr 1, 2026
enGene Holdings Inc. (NASDAQ:ENGNW) is a clinical-stage biotechnology company founded in 2023 and headquartered in Saint-Laurent, Canada. The company operates through its subsidiary enGene, Inc., and focuses on developing genetic medicines delivered to mucosal tissues and other organs. As a recently established biotech firm, enGene is currently in the clinical development phase with no commercial revenue, dedicating its resources to advancing its lead therapeutic candidate through regulatory trials for cancer treatment.
Similar companies
Latest newsMore news →
Richard Glickman resigned as director and chairman of the Board of Directors of enGene Therapeutics Inc., effective July 15, 2026.51d agoenGene Therapeutics Inc. reported its financial results for the second quarter of fiscal year 2026.81d agoenGene Therapeutics Inc. announced the resignation of Chief Medical Officer Hussein Sweiti effective June 14, 2026, and the termination of Chief Financial Officer Ryan Daws and Chief Legal Officer Lee Giguere effective July 15, 2026.82d ago